Quest Diagnostics unveiled a first-to-market blood test for consumers that helps assess the potential risk of developing Alzheimer’s disease.

Are you at high risk for "forever chemicals" (PFAS) in your job or residential area? Now Quest Diagnostics can test you for it without a doctor.

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Quest Diagnostics’ Haystack minimal ...

The diagnostics company will open a lab with Corewell Health in 2027 and manage the not-for-profit health system’s existing ...

HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that detects and measures the level of PFAS.

Have you ever wanted to know the PFAS levels in your body? Quest Health is making them widely available, calling them the first-ever consumer-initiated PFAS test.

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J ...

Under the terms of the agreement, Quest will offer ctDx FIRST to healthcare providers in the United States seeking a minimally invasive liquid biopsy test option as a CDx for KRAZATI.

Narrow-moat Quest Diagnostics delivered second-quarter results that slightly exceeded our expectations on the top line, but that was offset by earnings that fell slightly short of our full-year ...

Quest Diagnostics (DGX) announced that the U.S. FDA has granted Breakthrough Device Designation for the company’s Haystack MRD test for ...